Published in Haematologica on July 26, 2011
Non-transfusion-dependent thalassemias. Haematologica (2013) 1.21
β-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med (2012) 1.14
Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol (2013) 1.03
Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica (2013) 0.99
Intestinal HIF2α promotes tissue-iron accumulation in disorders of iron overload with anemia. Proc Natl Acad Sci U S A (2013) 0.98
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol (2013) 0.95
Secondary haemochromatosis in a patient with thalassemia intermedia. Curr Health Sci J (2013) 0.86
Estimating tissue iron burden: current status and future prospects. Br J Haematol (2015) 0.81
Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: the ORIENT study. Haematologica (2014) 0.80
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. Eur J Haematol (2014) 0.80
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Ann Hematol (2012) 0.79
Beta-thalassaemia intermedia: evaluation of endocrine and bone complications. Biomed Res Int (2014) 0.79
Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions. Ther Clin Risk Manag (2016) 0.78
Iron Homeostasis and Trypanosoma brucei Associated Immunopathogenicity Development: A Battle/Quest for Iron. Biomed Res Int (2015) 0.76
Management of the thalassemias. Cold Spring Harb Perspect Med (2013) 0.76
β-Thalassemia Intermedia: A Bird's-Eye View. Turk J Haematol (2014) 0.76
Pulmonary hypertension in well-transfused thalassemia major patients. Blood Cells Mol Dis (2014) 0.76
Novel approach to reactive oxygen species in nontransfusion-dependent thalassemia. Biomed Res Int (2014) 0.76
Endocrine and bone complications in β-thalassemia intermedia: current understanding and treatment. Biomed Res Int (2015) 0.76
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. Am J Hematol (2013) 0.76
When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia. Vox Sang (2014) 0.75
Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes. Drug Des Devel Ther (2015) 0.75
MRI Measurements of Iron Load in Transfusion-Dependent Patients: Implementation, Challenges, and Pitfalls. Pediatr Blood Cancer (2015) 0.75
Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. Br J Haematol (2016) 0.75
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J (2001) 8.90
Iron-chelating therapy and the treatment of thalassemia. Blood (1997) 4.99
Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med (1994) 4.86
MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood (2005) 4.79
Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood (2004) 4.40
Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med (2000) 4.03
Iron-chelating therapy for transfusional iron overload. N Engl J Med (2011) 3.92
Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol (2004) 3.63
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract (2004) 3.36
Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial. Br Heart J (1992) 2.99
Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica (2007) 2.52
Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost (2006) 2.27
Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. J Clin Invest (2010) 2.18
Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med (2010) 2.04
Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol (2007) 1.85
Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost (2010) 1.71
Cardiac involvement in thalassemia intermedia: a multicenter study. Blood (2001) 1.67
Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest (2005) 1.58
Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol (2006) 1.57
Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol (2000) 1.56
Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol (2000) 1.54
Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood (2009) 1.50
Optimal management of β thalassaemia intermedia. Br J Haematol (2011) 1.41
Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood (2002) 1.40
Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Int J Hematol (2003) 1.23
High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood (2010) 1.22
Age-related complications in treatment-naïve patients with thalassaemia intermedia. Br J Haematol (2010) 1.18
Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia. Hematol Oncol Clin North Am (2010) 1.14
Redefining thalassemia as a hypercoagulable state. Ann N Y Acad Sci (2010) 1.04
Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion (2010) 1.04
Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol (2009) 1.00
Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica (2007) 1.00
Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica (2008) 0.97
Age-related changes in adaptation to severe anemia in childhood in developing countries. Proc Natl Acad Sci U S A (2007) 0.97
Thalassemia intermedia. Haematologica (1995) 0.96
Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Br J Haematol (2009) 0.96
Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol (1993) 0.96
Haem, haem oxygenase and ferritin in vascular endothelial cell injury. Nephrol Dial Transplant (2003) 0.95
Iron metabolism and ineffective erythropoiesis in beta-thalassemia mouse models. Ann N Y Acad Sci (2010) 0.93
Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Ann Hematol (2009) 0.93
Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Am J Hematol (2010) 0.92
Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost (2009) 0.89
No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermedia. Haematologica (2008) 0.88
Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion (2007) 0.85
First update of the Lebanese guidelines for osteoporosis assessment and treatment. J Clin Densitom (2008) 0.77
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica (2004) 5.21
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet (2011) 4.27
Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica (2005) 2.64
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica (2006) 2.54
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood (2005) 2.45
Use of antidepressants and risk of colorectal cancer: a nested case-control study. Lancet Oncol (2006) 2.36
On T2* magnetic resonance and cardiac iron. Circulation (2011) 2.33
Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost (2006) 2.27
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood (2009) 2.20
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Improved R2* measurements in myocardial iron overload. J Magn Reson Imaging (2006) 2.09
Longitudinal analysis of heart and liver iron in thalassemia major. Blood (2008) 1.94
MRI detects myocardial iron in the human heart. Magn Reson Med (2006) 1.90
Knowledge, attitude and practice of tobacco smoking by medical students in Riyadh, Saudi Arabia. Ann Thorac Med (2010) 1.75
Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol (2007) 1.74
Peripheral vasoconstriction and abnormal parasympathetic response to sighs and transient hypoxia in sickle cell disease. Am J Respir Crit Care Med (2011) 1.71
Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. Lancet Oncol (2007) 1.57
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica (2008) 1.54
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood (2012) 1.49
Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease. Am J Hematol (2009) 1.48
Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev (2012) 1.48
Use of complementary and alternative medicine by patients with cancer in Saudi Arabia. J Altern Complement Med (2012) 1.46
Nutritional deficiencies in iron overloaded patients with hemoglobinopathies. Am J Hematol (2009) 1.42
Optimal management of β thalassaemia intermedia. Br J Haematol (2011) 1.41
Simulation training in endotracheal intubation in a pediatric residency. Middle East J Anaesthesiol (2014) 1.40
Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. Br J Haematol (2014) 1.40
R2* imaging of transfusional iron burden at 3T and comparison with 1.5T. J Magn Reson Imaging (2007) 1.38
Reliability of skin biopsies in determining accurate tumor margins: a retrospective study after Mohs micrographic surgery. Dermatol Surg (2014) 1.38
Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. Eur Spine J (2010) 1.36
Magnetic resonance detection of kidney iron deposition in sickle cell disease: a marker of chronic hemolysis. J Magn Reson Imaging (2008) 1.34
Thrombosis and sickle cell disease. Semin Thromb Hemost (2011) 1.32
Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica (2004) 1.30
How I treat transfusional iron overload. Blood (2012) 1.29
Psychosocial aspects and psychiatric disorders in young adult with thalassemia major. Intern Emerg Med (2008) 1.27
Mechanisms of tissue-iron relaxivity: nuclear magnetic resonance studies of human liver biopsy specimens. Magn Reson Med (2005) 1.22
Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol (2004) 1.22
The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol (2002) 1.21
An update on iron chelation therapy. Blood Transfus (2012) 1.19
Bone disease and skeletal complications in patients with β thalassemia major. Bone (2010) 1.19
Age-related complications in treatment-naïve patients with thalassaemia intermedia. Br J Haematol (2010) 1.18
Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood (2010) 1.17
High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol (2009) 1.16
A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica (2008) 1.16
β-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med (2012) 1.14
Pregnancy outcome in patients with beta-thalassemia intermedia at two tertiary care centers, in Beirut and Milan. Haematologica (2008) 1.13
A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol (2011) 1.12
Reproducibility of carotid intima-media thickness measurements in young adults. Radiology (2008) 1.10
Effect of erythromycin before endoscopy in patients presenting with variceal bleeding: a prospective, randomized, double-blind, placebo-controlled trial. Gastrointest Endosc (2010) 1.10
Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol Med (2010) 1.10
Relaxivity-iron calibration in hepatic iron overload: probing underlying biophysical mechanisms using a Monte Carlo model. Magn Reson Med (2010) 1.09
MR imaging of newborns by using an MR-compatible incubator with integrated radiofrequency coils: initial experience. Radiology (2004) 1.09
Spleen R2 and R2* in iron-overloaded patients with sickle cell disease and thalassemia major. J Magn Reson Imaging (2009) 1.09
Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood (2013) 1.08
Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One (2011) 1.08
Cardiac abnormalities in children with sickle cell anemia. Am J Hematol (2002) 1.07
Thalidomide and thrombosis. A meta-analysis. Thromb Haemost (2007) 1.07
The role of TMPRSS6 polymorphisms in iron deficiency anemia partially responsive to oral iron treatment. Am J Hematol (2015) 1.07
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica (2012) 1.07
Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol (2011) 1.07
Total anomalous pulmonary venous return involving drainage above, below, and to the heart: a mixed bag. J Am Soc Echocardiogr (2004) 1.07
Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: a Webthal study. Circulation (2013) 1.06
Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood (2009) 1.05
Redefining thalassemia as a hypercoagulable state. Ann N Y Acad Sci (2010) 1.04
Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica (2010) 1.04
What is the most appropriate formula to use in estimating glomerular filtration rate in adult Arabs without kidney disease? Ren Fail (2008) 1.01
Risk factors for pulmonary hypertension in patients with β thalassemia intermedia. Eur J Intern Med (2011) 1.01
Does repeated Ramadan fasting adversely affect kidney function in renal transplant patients? Transplantation (2008) 1.00
Solitary mediastinal lymph node metastasis in rectosigmoid carcinoma: a case report. Cases J (2008) 1.00
The acute porphyrias: a diagnostic and therapeutic challenge in internal and emergency medicine. Intern Emerg Med (2009) 1.00
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica (2014) 1.00
Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol (2011) 0.99
Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. Haematologica (2009) 0.99
The use of appropriate calibration curves corrects for systematic differences in liver R2* values measured using different software packages. Br J Haematol (2013) 0.99
Resveratrol accelerates erythroid maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic mice. Haematologica (2013) 0.99
History and current impact of cardiac magnetic resonance imaging on the management of iron overload. Circulation (2009) 0.97
Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica (2008) 0.97
Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Br J Haematol (2009) 0.96
Iron overload in β-thalassemia intermedia: an emerging concern. Curr Opin Hematol (2013) 0.96
Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. Blood (2011) 0.96
Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis (2011) 0.95
Systemic endothelial dysfunction in children with idiopathic pulmonary arterial hypertension correlates with disease severity. J Heart Lung Transplant (2012) 0.94
Spectral domain optical coherence tomography in children: normative data and biometric correlations. BMC Ophthalmol (2014) 0.94
The prevalence and correlates of depression and anxiety in a sample of diabetic patients in Sharjah, United Arab Emirates. BMC Fam Pract (2010) 0.93
Severe asthma exacerbation: role of acute Chlamydophila pneumoniae and Mycoplasma pneumoniae infection. Respir Res (2008) 0.93
Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Ann Hematol (2009) 0.93
Selective toxicity of dihydroartemisinin on human CD34+ erythroid cell differentiation. Toxicology (2010) 0.93
Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Am J Hematol (2010) 0.92